Drug Trial Radar · NCT01863225
Characterization of Multi-dose RVX000222 in Combination With Statin Treatment in Dyslipidemia
Last checked: Nov 19, 2026Latest source record: May 12, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
13
Actual
Start
May 2013
Primary completion
Jun 2013
Study completion Jun 2013
Sponsor
- Lead sponsor
- Resverlogix CorpIndustry
- Sponsor type
- Industry
- Collaborators
- South Australian Health and Medical Research Institute
- First posted
- May 27, 2013
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Basic science
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to characterize the pharmacokinetics of multi-dose RVX000222 and atorvastatin and rosuvastatin when either statin is administered in combination with RVX000222 in subjects with dyslipidemia.
Conditions
- Dyslipidemia
- Coronary Artery Disease
Interventions
RVX000222Drug
capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 14-days
RosuvastatinDrug
20 mg daily, 28-42 days
AtorvastatinDrug
40 mg daily, 28-42 days
RosuvastatinDrug
40 mg daily, 28-42 days
AtorvastatinDrug
80 mg daily, 28-42 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Characterization of the pharmacokinetics of RVX000222 capsule formulation in combination with either atorvastatin or rosuvastatin in patients with dyslipidemia.Time frame: 14 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Royal Adelaide Hospital / CMAX
Adelaide, South Australia, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.